22 hours Ago
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA , April 2, 2025 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") announced today its participation in the following upcoming investor conferences: Needham 24 th Annual Virtual Healthcare Conference, April 7-10, 2025 Wells Fargo Virtual Private Biopharma Symposium, May 7, 2025 During these events, Company management will participate in one-on-one meetings with investors. At the Needham event, Stéphane van Rooijen, President and CEO of Flamingo, and Andrew E. Denker , MD, PhD, Chief Medical Officer, will present a virtual company overview on April 10, 2025 , at 11:45 am ET .
About Flamingo Therapeutics Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, and VIB. Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC).
A Phase I investigator initiated trial study has also been initiated evaluating danvatirsen as a monotherapy and in combination with venetoclax in AML/MDS patients. For more information on Flamingo, please visit: https://flamingotx.com PEMDA-HN (head and neck cancer) on clinicaltrials.
gov: https://clinicaltrials.gov/study/NCT05814666 Danvatirsen monotherapy followed by combination with venetoclax in relapsed/ refractory AML and MDS on clincaltrials.gov: https://classic.
clinicaltrials.gov/ct2/show/NCT05986240 Please engage with us on LinkedIn: https://www.linkedin.
com/company/flamingo-therapeutics . Flamingo Media and Investor Contact: Amy Conrad Juniper Point (858) 366-3243 [email protected] SOURCE Flamingo Therapeutics.
